Wolters Kluwer Health
may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
your express consent. For more information, please refer to our Privacy Policy.

The cohort of patients co-infected with HIV and HCV needs a special approach to monitoring and treatment. The combination of these infectious pathologies negatively effects the prognosis and complicates therapy. At the same time, the majority of patients co-infected with HIV/HCV are injecting drug users, which further complicates their involvement in treatment process. Modern strategies for treatment of HCV by using new classes of antivirals will simplify treatment and increase the frequency of patients with SVR. In Russia, according to official statistics, the number of patients with HIV infection in 2014 was 742,611 people. Of these, 522,611 patients were involved in HIV care of which 221,441 people (42.4%) had chronic hepatitis C. The growing number of patients co-infected with HIV/HCV in recent years corresponds to an increasing number of people involved in care, indicating preservation of a significant number of cases of HIV infection due to injecting drug use. Thus, we can expect that the widespread introduction of modern treatment strategies in Russia will have a positive impact on the pace of development of co-infection and increase the length and quality of life of patients. In general, these data provide an opportunity to assess the situation with co-infection of HIV/HCV in Russian Federation, and are important for public health, the accumulation of necessary resources, the preparation of infrastructure and surveillance.